Filing Details

Accession Number:
0001209191-23-021559
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-29 19:30:14
Reporting Period:
2023-03-27
Accepted Time:
2023-03-29 19:30:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1693011 Inozyme Pharma Inc. INZY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1551966 Lorne Robert Hopfner C/O Inozyme Pharma, Inc.
321 Summer Street Suite 400
Boston MA 02210
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-27 51,074 $3.70 2,712,228 No 4 P Indirect See footnotes
Common Stock Acquisiton 2023-03-28 156,766 $4.16 2,868,994 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
Footnotes
  1. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.625 to $3.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
  2. 2,668,450 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 43,778 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").
  3. Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
  4. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.64 to $4.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (4).
  5. 2,690,845 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 178,149 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P.